US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Soligenix, Inc.

1.70

-0.0850-4.76%

Post-market: 1.700.00000.00%19:27 EDT

Volume:32.72K

Turnover:57.02K

Market Cap:5.55M

PE:-0.40

High:1.78

Open:1.75

Low:1.70

Close:1.79

Loading ...

Overview Company News Filings

Soligenix Inc. Conducted Annual Stockholders Meeting

Soligenix Inc reports results for the quarter ended March 31 - Earnings Summary

Soligenix Q1 EPS $(1.06) Misses $(0.67) Estimate

Soligenix Announces Recent Accomplishments and First Quarter 2025 Financial Results

THOMSON REUTERS

Soligenix Inc. Unveils Corporate Presentation Highlighting Advances in Rare Disease Treatments and Promising Pipeline

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.

Zacks Small Cap Research

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…

Zacks Small Cap Research

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…

Zacks Small Cap Research

IBN Initiates Coverage of Soligenix Inc.

BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

THOMSON REUTERS

Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Soligenix Inc expected to post a loss of 95 cents a share - Earnings Preview

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

SNGX: Presentation Highlights HyBryte Potential in CTCL…

Zacks Small Cap Research

Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison

THOMSON REUTERS

Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial

BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SNGX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SNGX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","market":"US","secType":"STK","nameCN":"Soligenix, Inc.","latestPrice":1.7,"timestamp":1750449600000,"preClose":1.785,"halted":0,"volume":32724,"hourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.7,"latestTime":"19:27 EDT","volume":78,"amount":137.96,"timestamp":1750462052112},"delay":0,"floatShares":3263678,"shares":3264346,"eps":-4.245498,"marketStatus":"Market Closed","change":-0.085,"latestTime":"06-20 16:00:00 EDT","open":1.75,"high":1.7797,"low":1.7,"amount":57020.2381332,"amplitude":0.04465,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.245498,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.785,"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.7,"latestTime":"19:27 EDT","volume":78,"amount":137.96,"timestamp":1750462052112},"volumeRatio":1.9220248692126765},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SNGX\",,,,,undefined,":{"symbol":"SNGX","floatShares":3263678,"roa":"-84.11%","roe":"-437.73%","lyrEps":-4.978626,"volumeRatio":1.9220248692126765,"shares":3264346,"dividePrice":0,"high":1.7797,"amplitude":0.04465,"preClose":1.785,"low":1.7,"week52Low":1.68,"pbRate":"1.54","psRate":"2369.51","week52High":14.8299,"institutionHeld":0.0101,"latestPrice":1.7,"eps":-4.245498,"divideRate":0,"volume":32724,"delay":0,"ttmEps":-4.245498,"open":1.75,"prevYearClose":2.695,"prevWeekClose":1.8,"prevMonthClose":1.89,"prevQuarterClose":2.15,"fiveDayClose":1.84,"twentyDayClose":1.88,"sixtyDayClose":2.37},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SNGX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2545170144","title":"Soligenix Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170144","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170144?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:06","pubTimestamp":1750449987,"startTime":"0","endTime":"0","summary":"Soligenix Inc. held its 2025 annual meeting of stockholders on June 20, 2025. During the meeting, several proposals were voted upon. The election of five directors was approved. The 2025 Equity Incentive Plan received approval. The ratification of Cherry Bekaert, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also approved. Lastly, the proposal to approve an adjournment of the Annual Meeting if necessary was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Jun","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL9Dp299:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2534875694","title":"Soligenix Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534875694","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534875694?lang=en_us&edition=fundamental","pubTime":"2025-05-09 21:30","pubTimestamp":1746797408,"startTime":"0","endTime":"0","summary":"Soligenix Inc reports results for the quarter ended March 31 - Earnings SummarySoligenix Inc SNGX.OQ reported a quarterly adjusted loss of $1.06 per share for the quarter ended March 31, higher than t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH1SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2534048893","title":"Soligenix Q1 EPS $(1.06) Misses $(0.67) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534048893","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534048893?lang=en_us&edition=fundamental","pubTime":"2025-05-09 19:36","pubTimestamp":1746790570,"startTime":"0","endTime":"0","summary":"Soligenix (NASDAQ:SNGX) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.67) by 58.21 percent. This is a 63.19 percent increase over losses of $(2.88) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45314645/soligenix-q1-eps-1-06-misses-0-67-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2534148853","title":"Soligenix Announces Recent Accomplishments and First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534148853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534148853?lang=en_us&edition=fundamental","pubTime":"2025-05-09 19:30","pubTimestamp":1746790205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nTUA3LYPP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2532851628","title":"Soligenix Inc. Unveils Corporate Presentation Highlighting Advances in Rare Disease Treatments and Promising Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2532851628","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532851628?lang=en_us&edition=fundamental","pubTime":"2025-05-02 01:00","pubTimestamp":1746118851,"startTime":"0","endTime":"0","summary":"Soligenix Inc., a late-stage biopharmaceutical company, has released a corporate presentation detailing its focus on developing products for rare diseases with unmet medical needs. The company is divided into two segments: Specialized BioTherapeutics, which targets orphan diseases in oncology and inflammation, and Public Health Solutions, which focuses on vaccines and therapeutics for military and civilian applications including ricin exposure and viral diseases like Ebola and COVID-19. Soligenix boasts a robust pipeline of products with fast track and orphan designations, potentially generating significant commercial returns. Notable developments include positive Phase 1/2 results for psoriasis treatment SGX302 and ongoing Phase 2a studies. The company is also conducting a confirmatory Phase 3 study for cutaneous T-cell lymphoma treatment HyBryte, with significant market opportunities. Collaborations with biotech, academia, and government agencies, along with non-dilutive government f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDLccSSvZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2530998766","title":"Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530998766","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530998766?lang=en_us&edition=fundamental","pubTime":"2025-04-25 00:09","pubTimestamp":1745510940,"startTime":"0","endTime":"0","summary":"David Bautz: Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris Schaber. He is the Chief Executive Officer of Soligenix, Inc. They are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates two business segments. The specialized biotherapeutic segment, which is what we're going to focus on today, along with the public health solutions segment. The stock trades on the NASDAQ under the symbol SNGX. Now, the company's lead asset, HyBryte, is currently in a confirmatory phase three trial for the treatment of cutaneous T-cell lymphoma, or CTCL. The company also has two phase two trials ongoing for SGX302 for the treatment of psoriasis and SGX945 for the treatment of Behet's disease. Soligenix is a company that we have covered for a nu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fireside-chat-christopher-schaber-chief-160900353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2527115562","title":"SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115562","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115562?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:38","pubTimestamp":1744634280,"startTime":"0","endTime":"0","summary":"Interim Data from IIS Study Shows 75% Response Rate and Three Complete Responses. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-updated-iis-data-shows-123800928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2527432159","title":"Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2527432159","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527432159?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile. \"The complete response rates observed, including three patients achieving a complete response on this study to date, as well as the consistent treatment response and safety profile across multiple HyBryte clinical studies, has been exciting to see,\" noted Dr. Kim, Principal Investigator of the IIS. \"In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease. With limited treatment options, especially in the early stages of their disease, CTCL pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/positive-outcome-75-ctcl-patients-113000163.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-outcome-75-ctcl-patients-113000163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNGX","BK4168","IDR","BK4139"],"gpt_icon":0},{"id":"2522380305","title":"SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…","url":"https://stock-news.laohu8.com/highlight/detail?id=2522380305","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522380305?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"CiVax Booster Enhances Protection from COVID-19 in NHPs. On March 25, 2025, Soligenix, Inc.  announced a publication that includes results from a prime-boost study in non-human primates  that showed the use of CiVax, the company’s thermostabilized subunit vaccine against SARS-CoV-2, following vaccination with a primary adenovirus vaccine  resulted in a robust immune response against SARS-CoV-2 variants.The ThermoVax platform has a number of advantages over other vaccine platforms, including its use of protein subunits without the need for strict cold-storage requirements. These most recent results show that CiVax can induce a rapid, robust immune response against SARS-CoV-2 variants even when administered after another primary vaccine series. Combined with a proven vaccine technology, these results show the company’s vaccine platform could be utilized for current threats as well as those that may emerge in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-preclinical-data-shows-civax-121500311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BNTX","SNGX"],"gpt_icon":0},{"id":"2522075375","title":"IBN Initiates Coverage of Soligenix Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522075375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522075375?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:30","pubTimestamp":1742905800,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, March 25, 2025  -- via IBN – Soligenix Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts.Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte  as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma . With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin  into psori","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ibn-initiates-coverage-soligenix-inc-123000018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","IE00B0JY6M65.USD","LU0143863198.USD","LU1102505762.USD","BK4588","LU1868838027.USD","LU0181495838.USD","LU1102505929.USD","BK4168","BK4535","LU0261950470.USD","LU1481012133.USD","DBP","LU0164881194.USD","LU0048575426.USD","BK4523","IE00B7N09G41.SGD","IBN","LU0823039010.USD","IE00BYTNYM70.SGD","IDR","LU0531971678.HKD","LU0251143458.SGD","LU0823038988.USD","BK4585","LU1868837722.USD","LU0828237940.HKD","LU0066902890.USD","BK4207","BK4139","LU0143863784.USD","SNGX","LU0264410563.USD","LU1868837565.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2522299180","title":"BRIEF-Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants","url":"https://stock-news.laohu8.com/highlight/detail?id=2522299180","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522299180?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:35","pubTimestamp":1742902554,"startTime":"0","endTime":"0","summary":"BRIEF-Soligenix Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25 (Reuters) - Soligenix Inc SNGX.O:SOLIGENIX ANNOUNCES PUBLICATION DEMO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q80B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521285354","title":"Soligenix Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2521285354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521285354?lang=en_us&edition=fundamental","pubTime":"2025-03-21 20:23","pubTimestamp":1742559826,"startTime":"0","endTime":"0","summary":"Soligenix Inc reports results for the quarter ended December 31 - Earnings SummarySoligenix Inc SNGX.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended December 31, higher ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL8N3Q40ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2521407754","title":"Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521407754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521407754?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA2DMC9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2521072414","title":"Press Release: Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521072414","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521072414?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556600,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024.Dr. Schaber continued, \"With approximately $7.8 million in cash at December 31, 2024, we are committed to disciplined resource allocation to achieve our strategic goals. While this cash balance provides operating runway through 2025, we continue to evaluate all strategic options, including partnership, merger and acquisition, government grants, and potential financing opportunities to advance our late-stage pipeline and the Company.\". with early-stage CTCL. To view this press release, please click here.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IDR","BK4022","03160","TM","R","BK4168","BK4604","MAB","BK4232","BK4585","BK4099","BK4139","SNGX","BK4555"],"gpt_icon":0},{"id":"2519010978","title":"Soligenix Inc  expected to post a loss of 95 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519010978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519010978?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:12","pubTimestamp":1741957926,"startTime":"0","endTime":"0","summary":"Soligenix Inc  expected to post a loss of95cents a share - Earnings Preview Soligenix Inc SNGX.OQ SNGX.O is expected to show a rise in quarterly revenue when it reports  results on March 17 (estimated","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX18F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX"],"gpt_icon":0},{"id":"2517086154","title":"HyBryte™ Treatment Studies Presented at Two Medical Conferences in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2517086154","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517086154?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy. Conference: USCLC Workshop \"Cutaneous Lymphomas in Special Populations\" March 6, Orlando, Florida. The official conference program can be found here.Presentation Title: Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL – a Phase 2 real world investigator-initiated study presented by Dr. Ellen Kim, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania.presented by Dr. Neal Bhatia, Director of Clinical Dermatology at Therapeutics Clinical Research and chief medical editor at Practical Dermatology. The official conference program can be found here.These presentations incorporate the Company's findings in recentsupportive studies which have demonstrated the utility of longer treatment times, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hybryte-treatment-studies-presented-two-123000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IDR","BSA","BK4139","BK4168","SNGX"],"gpt_icon":0},{"id":"2514067427","title":"SNGX: Presentation Highlights HyBryte Potential in CTCL…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514067427","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514067427?lang=en_us&edition=fundamental","pubTime":"2025-02-25 00:02","pubTimestamp":1740412920,"startTime":"0","endTime":"0","summary":"In January 2025, Dr. Neal Bhatia presented at two dermatology conferences on “Off-Label Uses of PDT” . Dr. Bhatia is the Director of Clinical Dermatology at Therapeutics Clinical Research, a member of Soligenix’s  scientific advisory board, and was a participating investigator in the Phase 3 HyBryte trial. During his presentation, Dr. Bhatia discussed the efficacy results from multiple studies of HyBryte along with results from studies examining Valchlor , also known as nitrogen mustard , which is indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T cell lymphoma . Valchlor was approved based in part on the results of a Phase 3 trial in which it was compared to a compounded 0.02% mechlorethamine ointment . The study was successful and showed that Valchlor was superior to the ointment .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sngx-presentation-highlights-hybryte-potential-160200810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4021","NM","BK4139","SNGX"],"gpt_icon":0},{"id":"2510859400","title":"Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859400?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:33","pubTimestamp":1739190790,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nFWN3P10G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNGX"],"gpt_icon":0},{"id":"2503524270","title":"Soligenix’s HyBryte shows efficacy in T-cell lymphoma trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503524270","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503524270?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:35","pubTimestamp":1736858116,"startTime":"0","endTime":"0","summary":"Soligenix (SNGX) announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soligenixs-hybryte-shows-efficacy-in-t-cell-lymphoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNGX","BK4139"],"gpt_icon":0},{"id":"2503241045","title":"BRIEF-HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2503241045","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503241045?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:34","pubTimestamp":1736858043,"startTime":"0","endTime":"0","summary":"BRIEF-HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJan 14 (Reuters) - Soligenix Inc SNGX.O:HYBRYTE EXPANDED TREATMENT CONTINUES TO DEMO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNGX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SNGX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-09","symbol":"SNGX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.06},{"market":"US","date":"2025-03-21","symbol":"SNGX","fiscalQuarterEnding":"2024/12","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742529600000,"reportTimeType":"pre","actualEps":-1.14},{"market":"US","date":"2024-11-08","symbol":"SNGX","fiscalQuarterEnding":"2024/09","expectedEps":-1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731042000000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2024-08-09","symbol":"SNGX","fiscalQuarterEnding":"2024/06","expectedEps":-2.11,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-1.31},{"market":"US","date":"2024-06-06","symbol":"SNGX","defaultRemindTime":1717680600000,"type":"split","dateTimestamp":1717646400000,"forFactor":16,"toFactor":1,"ratio":16}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SNGX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SNGX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SNGX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SNGX","date":"2025-06-18","current":-0.61283,"percent":0.831169,"low":-5.464746,"twenty":-3.273592,"median":-1.563577,"eighty":-0.712183,"high":-0.277411,"avg":-1.873919,"sd":1.225252,"marketCap":5875822},"quantilePoints":[{"date":"2020-06-26","current":-3.631049,"twenty":-3.744873,"median":-2.957629,"eighty":-2.106354,"marketCap":55545243},{"date":"2020-07-02","current":-3.405194,"twenty":-3.729793,"median":-2.957629,"eighty":-2.106354,"marketCap":52090276},{"date":"2020-07-10","current":-3.526808,"twenty":-3.712662,"median":-2.957629,"eighty":-2.106354,"marketCap":53950642},{"date":"2020-07-17","current":-4.183339,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63993787},{"date":"2020-07-24","current":-4.164923,"twenty":-3.710161,"median":-2.957629,"eighty":-2.106354,"marketCap":63712077},{"date":"2020-07-31","current":-4.202786,"twenty":-3.71974,"median":-2.957629,"eighty":-2.106354,"marketCap":64291278},{"date":"2020-08-07","current":-4.278512,"twenty":-3.73529,"median":-2.958383,"eighty":-2.106354,"marketCap":65449680},{"date":"2020-08-14","current":-3.798616,"twenty":-3.745836,"median":-2.963367,"eighty":-2.106354,"marketCap":60589987},{"date":"2020-08-21","current":-4.041878,"twenty":-3.787557,"median":-2.963367,"eighty":-2.106354,"marketCap":64470134},{"date":"2020-08-28","current":-3.686342,"twenty":-3.798616,"median":-2.963367,"eighty":-2.106354,"marketCap":58799151},{"date":"2020-09-04","current":-3.368231,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":53725112},{"date":"2020-09-11","current":-3.555355,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":56709840},{"date":"2020-09-18","current":-3.742479,"twenty":-3.793641,"median":-2.963367,"eighty":-2.106354,"marketCap":59694570},{"date":"2020-09-25","current":-3.181107,"twenty":-3.792424,"median":-2.965739,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-10-02","current":-3.255957,"twenty":-3.792424,"median":-2.974005,"eighty":-2.107674,"marketCap":51934274},{"date":"2020-10-09","current":-3.349519,"twenty":-3.792424,"median":-2.993101,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-16","current":-3.349519,"twenty":-3.792424,"median":-2.996669,"eighty":-2.107674,"marketCap":53426639},{"date":"2020-10-23","current":-3.405656,"twenty":-3.792424,"median":-3.016006,"eighty":-2.107674,"marketCap":54322058},{"date":"2020-10-30","current":-3.181107,"twenty":-3.792424,"median":-3.02874,"eighty":-2.107674,"marketCap":50740384},{"date":"2020-11-06","current":-3.068833,"twenty":-3.792424,"median":-3.03163,"eighty":-2.107674,"marketCap":48949546},{"date":"2020-11-13","current":-3.576924,"twenty":-3.792424,"median":-3.032343,"eighty":-2.107674,"marketCap":53725112},{"date":"2020-11-20","current":-4.371797,"twenty":-3.807236,"median":-3.032343,"eighty":-2.107674,"marketCap":65664026},{"date":"2020-11-27","current":-4.332053,"twenty":-3.808915,"median":-3.032343,"eighty":-2.107674,"marketCap":65067080},{"date":"2020-12-04","current":-4.967951,"twenty":-3.822057,"median":-3.032343,"eighty":-2.113513,"marketCap":74618212},{"date":"2020-12-11","current":-4.570515,"twenty":-3.833505,"median":-3.035911,"eighty":-2.115839,"marketCap":68648754},{"date":"2020-12-18","current":-5.325643,"twenty":-3.84402,"median":-3.041386,"eighty":-2.116451,"marketCap":79990722},{"date":"2020-12-24","current":-2.662821,"twenty":-3.835838,"median":-3.035911,"eighty":-2.116451,"marketCap":39995360},{"date":"2020-12-31","current":-2.543591,"twenty":-3.825781,"median":-3.032517,"eighty":-2.116451,"marketCap":38204524},{"date":"2021-01-08","current":-2.821796,"twenty":-3.820118,"median":-3.031986,"eighty":-2.116451,"marketCap":42383144},{"date":"2021-01-15","current":-2.997624,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":45024063},{"date":"2021-01-22","current":-3.605533,"twenty":-3.820118,"median":-3.02874,"eighty":-2.116451,"marketCap":54154817},{"date":"2021-01-29","current":-3.249173,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":48802306},{"date":"2021-02-05","current":-3.458797,"twenty":-3.822057,"median":-3.02874,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-02-12","current":-4.485954,"twenty":-3.822137,"median":-3.02874,"eighty":-2.116451,"marketCap":67378666},{"date":"2021-02-19","current":-3.982857,"twenty":-3.833505,"median":-3.030551,"eighty":-2.116451,"marketCap":59822181},{"date":"2021-02-26","current":-3.458797,"twenty":-3.833505,"median":-3.03163,"eighty":-2.116451,"marketCap":51950841},{"date":"2021-03-05","current":-3.207248,"twenty":-3.835264,"median":-3.031519,"eighty":-2.11619,"marketCap":48172598},{"date":"2021-03-12","current":-3.75227,"twenty":-3.835264,"median":-3.03243,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-19","current":-3.75227,"twenty":-3.83612,"median":-3.040991,"eighty":-2.11619,"marketCap":56358791},{"date":"2021-03-26","current":-3.270135,"twenty":-3.835838,"median":-3.042299,"eighty":-2.116451,"marketCap":49117159},{"date":"2021-04-01","current":-3.529516,"twenty":-3.826467,"median":-3.042299,"eighty":-2.116451,"marketCap":62431916},{"date":"2021-04-09","current":-3.41639,"twenty":-3.822157,"median":-3.042299,"eighty":-2.11619,"marketCap":60430892},{"date":"2021-04-16","current":-2.963888,"twenty":-3.822157,"median":-3.041843,"eighty":-2.11619,"marketCap":52426802},{"date":"2021-04-23","current":-3.212764,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":56829052},{"date":"2021-04-30","current":-3.258014,"twenty":-3.822057,"median":-3.040991,"eighty":-2.11619,"marketCap":57629461},{"date":"2021-05-07","current":-2.896013,"twenty":-3.808915,"median":-3.033651,"eighty":-2.11619,"marketCap":51226187},{"date":"2021-05-14","current":-2.013634,"twenty":-3.807849,"median":-3.030979,"eighty":-2.11619,"marketCap":35618208},{"date":"2021-05-21","current":-3.342664,"twenty":-3.807849,"median":-3.034785,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-05-28","current":-3.278382,"twenty":-3.807849,"median":-3.042299,"eighty":-2.11619,"marketCap":40880324},{"date":"2021-06-04","current":-3.471227,"twenty":-3.807849,"median":-3.047644,"eighty":-2.11619,"marketCap":43285047},{"date":"2021-06-11","current":-3.792638,"twenty":-3.808915,"median":-3.051016,"eighty":-2.11619,"marketCap":47292924},{"date":"2021-06-18","current":-3.599792,"twenty":-3.815158,"median":-3.058506,"eighty":-2.11619,"marketCap":44888198},{"date":"2021-06-25","current":-3.696215,"twenty":-3.815158,"median":-3.073824,"eighty":-2.11619,"marketCap":46090561},{"date":"2021-07-02","current":-3.342664,"twenty":-3.814599,"median":-3.085535,"eighty":-2.11619,"marketCap":41681899},{"date":"2021-07-09","current":-3.406946,"twenty":-3.820677,"median":-3.087545,"eighty":-2.11619,"marketCap":42483474},{"date":"2021-07-16","current":-3.149818,"twenty":-3.820677,"median":-3.091406,"eighty":-2.11619,"marketCap":39277173},{"date":"2021-07-23","current":-3.10032,"twenty":-3.820677,"median":-3.101159,"eighty":-2.11619,"marketCap":38659960},{"date":"2021-07-30","current":-3.063037,"twenty":-3.820677,"median":-3.120558,"eighty":-2.11619,"marketCap":38195046},{"date":"2021-08-06","current":-3.2141,"twenty":-3.820677,"median":-3.123123,"eighty":-2.11619,"marketCap":40078748},{"date":"2021-08-13","current":-3.271976,"twenty":-3.820677,"median":-3.12497,"eighty":-2.116451,"marketCap":37922108},{"date":"2021-08-20","current":-3.183049,"twenty":-3.820677,"median":-3.127219,"eighty":-2.128852,"marketCap":36891443},{"date":"2021-08-27","current":-3.529416,"twenty":-3.819297,"median":-3.140414,"eighty":-2.139444,"marketCap":40905829},{"date":"2021-09-03","current":-3.806233,"twenty":-3.819297,"median":-3.149818,"eighty":-2.140169,"marketCap":44114128},{"date":"2021-09-10","current":-4.013846,"twenty":-3.822057,"median":-3.152361,"eighty":-2.145333,"marketCap":46520354},{"date":"2021-09-17","current":-3.737029,"twenty":-3.822117,"median":-3.16435,"eighty":-2.145333,"marketCap":43312052},{"date":"2021-09-24","current":-3.546717,"twenty":-3.822117,"median":-3.180179,"eighty":-2.145333,"marketCap":41106347},{"date":"2021-10-01","current":-3.633222,"twenty":-3.822117,"median":-3.181533,"eighty":-2.145333,"marketCap":42108942},{"date":"2021-10-08","current":-3.59862,"twenty":-3.822117,"median":-3.189617,"eighty":-2.145333,"marketCap":41707904},{"date":"2021-10-15","current":-3.806233,"twenty":-3.822117,"median":-3.197852,"eighty":-2.150499,"marketCap":44114128},{"date":"2021-10-22","current":-3.494814,"twenty":-3.822117,"median":-3.211097,"eighty":-2.154035,"marketCap":40504791},{"date":"2021-10-29","current":-3.494814,"twenty":-3.822117,"median":-3.2141,"eighty":-2.161849,"marketCap":40504791},{"date":"2021-11-05","current":-3.42561,"twenty":-3.822117,"median":-3.220267,"eighty":-2.162699,"marketCap":39702715},{"date":"2021-11-12","current":-2.916544,"twenty":-3.822117,"median":-3.222002,"eighty":-2.170406,"marketCap":39044830},{"date":"2021-11-19","current":-2.741366,"twenty":-3.822117,"median":-3.218265,"eighty":-2.170406,"marketCap":36699653},{"date":"2021-11-26","current":-2.875872,"twenty":-3.822117,"median":-3.216049,"eighty":-2.170406,"marketCap":38500338},{"date":"2021-12-03","current":-2.562024,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":34298742},{"date":"2021-12-10","current":-2.446092,"twenty":-3.822117,"median":-3.2141,"eighty":-2.170406,"marketCap":32746723},{"date":"2021-12-17","current":-2.394211,"twenty":-3.822117,"median":-3.211931,"eighty":-2.170406,"marketCap":32052174},{"date":"2021-12-23","current":-2.458582,"twenty":-3.822117,"median":-3.203637,"eighty":-2.170406,"marketCap":32913930},{"date":"2021-12-31","current":-2.114631,"twenty":-3.822117,"median":-3.191039,"eighty":-2.169084,"marketCap":28309324},{"date":"2022-01-07","current":-2.217909,"twenty":-3.822097,"median":-3.181959,"eighty":-2.166201,"marketCap":29691947},{"date":"2022-01-14","current":-2.069155,"twenty":-3.813481,"median":-3.181107,"eighty":-2.161849,"marketCap":27700521},{"date":"2022-01-21","current":-2.036489,"twenty":-3.810294,"median":-3.1662,"eighty":-2.161849,"marketCap":27263212},{"date":"2022-01-28","current":-1.97436,"twenty":-3.809605,"median":-3.158329,"eighty":-2.15359,"marketCap":26431467},{"date":"2022-02-04","current":-1.986209,"twenty":-3.809605,"median":-3.149818,"eighty":-2.148285,"marketCap":26590099},{"date":"2022-02-11","current":-2.014712,"twenty":-3.809605,"median":-3.144477,"eighty":-2.14007,"marketCap":26971673},{"date":"2022-02-18","current":-2.17772,"twenty":-3.809605,"median":-3.132783,"eighty":-2.139444,"marketCap":29153928},{"date":"2022-02-25","current":-2.306142,"twenty":-3.809605,"median":-3.129679,"eighty":-2.139444,"marketCap":30873154},{"date":"2022-03-04","current":-2.145054,"twenty":-3.809605,"median":-3.129679,"eighty":-2.138219,"marketCap":28716619},{"date":"2022-03-11","current":-2.312226,"twenty":-3.809605,"median":-3.124184,"eighty":-2.138219,"marketCap":30954613},{"date":"2022-03-18","current":-2.222556,"twenty":-3.806233,"median":-3.11997,"eighty":-2.138219,"marketCap":29754157},{"date":"2022-03-25","current":-2.309344,"twenty":-3.806233,"median":-3.105034,"eighty":-2.138219,"marketCap":30916027},{"date":"2022-04-01","current":-2.532554,"twenty":-3.806233,"median":-3.105034,"eighty":-2.139763,"marketCap":31786020},{"date":"2022-04-08","current":-2.529132,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":31743066},{"date":"2022-04-14","current":-2.481219,"twenty":-3.806233,"median":-3.105034,"eighty":-2.150636,"marketCap":31141708},{"date":"2022-04-22","current":-2.102362,"twenty":-3.806233,"median":-3.105034,"eighty":-2.152006,"marketCap":26386692},{"date":"2022-04-29","current":-1.80975,"twenty":-3.806233,"median":-3.105034,"eighty":-2.14463,"marketCap":22714119},{"date":"2022-05-06","current":-1.772104,"twenty":-3.806233,"median":-3.105034,"eighty":-2.142794,"marketCap":22241624},{"date":"2022-05-13","current":-1.178605,"twenty":-3.806233,"median":-3.100739,"eighty":-2.140196,"marketCap":17133992},{"date":"2022-05-20","current":-1.543144,"twenty":-3.806233,"median":-3.091406,"eighty":-2.139444,"marketCap":22433476},{"date":"2022-05-27","current":-1.77383,"twenty":-3.806233,"median":-3.089475,"eighty":-2.129342,"marketCap":25787088},{"date":"2022-06-03","current":-1.514419,"twenty":-3.806233,"median":-3.087545,"eighty":-2.119815,"marketCap":22015888},{"date":"2022-06-10","current":-1.776792,"twenty":-3.806233,"median":-3.087545,"eighty":-2.115527,"marketCap":25830138},{"date":"2022-06-17","current":-1.687952,"twenty":-3.806233,"median":-3.087545,"eighty":-2.100887,"marketCap":24538630},{"date":"2022-06-24","current":-1.617473,"twenty":-3.806233,"median":-3.087545,"eighty":-2.092935,"marketCap":23514034},{"date":"2022-07-01","current":-1.719934,"twenty":-3.806233,"median":-3.087545,"eighty":-2.086976,"marketCap":25003573},{"date":"2022-07-08","current":-1.762281,"twenty":-3.806233,"median":-3.087545,"eighty":-2.078536,"marketCap":25619192},{"date":"2022-07-15","current":-2.025543,"twenty":-3.806233,"median":-3.087545,"eighty":-2.0727,"marketCap":29446357},{"date":"2022-07-22","current":-2.259783,"twenty":-3.806233,"median":-3.077014,"eighty":-2.0727,"marketCap":32851632},{"date":"2022-07-29","current":-2.592339,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":37686173},{"date":"2022-08-05","current":-2.679994,"twenty":-3.806233,"median":-3.070415,"eighty":-2.0727,"marketCap":38960460},{"date":"2022-08-12","current":-2.539174,"twenty":-3.806233,"median":-3.068833,"eighty":-2.0727,"marketCap":38156702},{"date":"2022-08-19","current":-2.380834,"twenty":-3.793261,"median":-3.057725,"eighty":-2.0727,"marketCap":35777295},{"date":"2022-08-26","current":-2.280438,"twenty":-3.77381,"median":-3.037933,"eighty":-2.0727,"marketCap":34268616},{"date":"2022-09-02","current":-2.065302,"twenty":-3.75227,"median":-3.012696,"eighty":-2.072608,"marketCap":31035726},{"date":"2022-09-09","current":-1.986419,"twenty":-3.744873,"median":-2.99389,"eighty":-2.068643,"marketCap":29850333},{"date":"2022-09-16","current":-1.921878,"twenty":-3.736351,"median":-2.972351,"eighty":-2.06071,"marketCap":28880466},{"date":"2022-09-23","current":-1.455464,"twenty":-3.71974,"median":-2.963888,"eighty":-2.050413,"marketCap":21871566},{"date":"2022-09-30","current":-1.252663,"twenty":-3.703324,"median":-2.929273,"eighty":-2.049272,"marketCap":18824029},{"date":"2022-10-07","current":-1.641628,"twenty":-3.69525,"median":-2.907735,"eighty":-2.046565,"marketCap":24669091},{"date":"2022-10-14","current":-1.686663,"twenty":-3.686342,"median":-2.894033,"eighty":-2.042346,"marketCap":25345843},{"date":"2022-10-21","current":-1.804558,"twenty":-3.668494,"median":-2.865205,"eighty":-2.037717,"marketCap":27117466},{"date":"2022-10-28","current":-2.007933,"twenty":-3.667825,"median":-2.841668,"eighty":-2.029514,"marketCap":30173622},{"date":"2022-11-04","current":-1.893481,"twenty":-3.66653,"median":-2.8149,"eighty":-2.026959,"marketCap":28453728},{"date":"2022-11-11","current":-2.05165,"twenty":-3.663597,"median":-2.797124,"eighty":-2.021049,"marketCap":30259092},{"date":"2022-11-18","current":-1.905104,"twenty":-3.648917,"median":-2.778014,"eighty":-2.01711,"marketCap":28097730},{"date":"2022-11-25","current":-1.699939,"twenty":-3.641768,"median":-2.743928,"eighty":-2.014281,"marketCap":25071819},{"date":"2022-12-02","current":-1.64132,"twenty":-3.633222,"median":-2.735277,"eighty":-2.004814,"marketCap":24207273},{"date":"2022-12-09","current":-1.533755,"twenty":-3.633222,"median":-2.711283,"eighty":-1.996265,"marketCap":22620834},{"date":"2022-12-16","current":-1.846485,"twenty":-3.633222,"median":-2.682693,"eighty":-1.984215,"marketCap":27233184},{"date":"2022-12-23","current":-1.891329,"twenty":-3.633222,"median":-2.662821,"eighty":-1.97859,"marketCap":27894562},{"date":"2022-12-30","current":-1.32478,"twenty":-3.633222,"median":-2.64295,"eighty":-1.974296,"marketCap":19538728},{"date":"2023-01-06","current":-1.410357,"twenty":-3.630477,"median":-2.626074,"eighty":-1.970255,"marketCap":20800882},{"date":"2023-01-13","current":-1.377155,"twenty":-3.619207,"median":-2.596781,"eighty":-1.964148,"marketCap":20311194},{"date":"2023-01-20","current":-1.469416,"twenty":-3.619207,"median":-2.584653,"eighty":-1.961265,"marketCap":21671919},{"date":"2023-01-27","current":-1.409182,"twenty":-3.619207,"median":-2.562024,"eighty":-1.955717,"marketCap":20783547},{"date":"2023-02-03","current":-1.351886,"twenty":-3.615611,"median":-2.546439,"eighty":-1.950333,"marketCap":19938511},{"date":"2023-02-10","current":-1.047974,"twenty":-3.615611,"median":-2.539174,"eighty":-1.93629,"marketCap":15456214},{"date":"2023-02-17","current":-0.812914,"twenty":-3.615611,"median":-2.519549,"eighty":-1.920521,"marketCap":11989399},{"date":"2023-02-24","current":-0.744355,"twenty":-3.615611,"median":-2.50894,"eighty":-1.916691,"marketCap":10978245},{"date":"2023-03-03","current":-0.579814,"twenty":-3.615611,"median":-2.50315,"eighty":-1.905104,"marketCap":8551475},{"date":"2023-03-10","current":-0.628784,"twenty":-3.615611,"median":-2.498294,"eighty":-1.893481,"marketCap":9273728},{"date":"2023-03-17","current":-0.45249,"twenty":-3.615611,"median":-2.494874,"eighty":-1.873469,"marketCap":6673617},{"date":"2023-03-24","current":-0.360425,"twenty":-3.615611,"median":-2.490459,"eighty":-1.864593,"marketCap":5315782},{"date":"2023-03-31","current":-0.385889,"twenty":-3.614644,"median":-2.487664,"eighty":-1.852184,"marketCap":5691353},{"date":"2023-04-06","current":-0.368498,"twenty":-3.614644,"median":-2.487664,"eighty":-1.838884,"marketCap":5084661},{"date":"2023-04-14","current":-0.343373,"twenty":-3.615611,"median":-2.488267,"eighty":-1.81823,"marketCap":4737979},{"date":"2023-04-21","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.806924,"marketCap":4298921},{"date":"2023-04-28","current":-0.311554,"twenty":-3.615611,"median":-2.488267,"eighty":-1.796476,"marketCap":4298921},{"date":"2023-05-05","current":-0.486536,"twenty":-3.615611,"median":-2.488267,"eighty":-1.780665,"marketCap":6713384},{"date":"2023-05-12","current":-0.530952,"twenty":-3.615611,"median":-2.488267,"eighty":-1.774785,"marketCap":7326252},{"date":"2023-05-19","current":-0.450777,"twenty":-3.615611,"median":-2.488267,"eighty":-1.773356,"marketCap":4731101},{"date":"2023-05-26","current":-0.548639,"twenty":-3.615611,"median":-2.488267,"eighty":-1.762981,"marketCap":5758198},{"date":"2023-06-02","current":-0.556758,"twenty":-3.615611,"median":-2.488267,"eighty":-1.761231,"marketCap":5843414},{"date":"2023-06-09","current":-0.568435,"twenty":-3.615611,"median":-2.488267,"eighty":-1.758431,"marketCap":5965964},{"date":"2023-06-16","current":-0.553201,"twenty":-3.615611,"median":-2.488267,"eighty":-1.753075,"marketCap":5806081},{"date":"2023-06-23","current":-0.549104,"twenty":-3.616579,"median":-2.489363,"eighty":-1.755221,"marketCap":5763076},{"date":"2023-06-30","current":-0.549025,"twenty":-3.617546,"median":-2.490459,"eighty":-1.751843,"marketCap":5762256},{"date":"2023-07-07","current":-0.561243,"twenty":-3.617546,"median":-2.490459,"eighty":-1.719975,"marketCap":5890486},{"date":"2023-07-14","current":-0.534333,"twenty":-3.617546,"median":-2.490459,"eighty":-1.701031,"marketCap":5608055},{"date":"2023-07-21","current":-0.517398,"twenty":-3.617546,"median":-2.488267,"eighty":-1.696019,"marketCap":5430317},{"date":"2023-07-28","current":-0.487163,"twenty":-3.617546,"median":-2.48706,"eighty":-1.691433,"marketCap":5112988},{"date":"2023-08-04","current":-0.458552,"twenty":-3.617546,"median":-2.471478,"eighty":-1.68556,"marketCap":4812701},{"date":"2023-08-11","current":-0.492307,"twenty":-3.605533,"median":-2.464449,"eighty":-1.673383,"marketCap":5166973},{"date":"2023-08-18","current":-0.451047,"twenty":-3.604385,"median":-2.451581,"eighty":-1.658517,"marketCap":4733931},{"date":"2023-08-25","current":-0.474846,"twenty":-3.599792,"median":-2.429294,"eighty":-1.650503,"marketCap":4615829},{"date":"2023-09-01","current":-0.455119,"twenty":-3.59581,"median":-2.407007,"eighty":-1.641321,"marketCap":4424070},{"date":"2023-09-08","current":-0.515598,"twenty":-3.574766,"median":-2.401897,"eighty":-1.635487,"marketCap":5011970},{"date":"2023-09-15","current":-0.457243,"twenty":-3.566924,"median":-2.38362,"eighty":-1.627894,"marketCap":4444715},{"date":"2023-09-22","current":-0.50771,"twenty":-3.560315,"median":-2.374811,"eighty":-1.617598,"marketCap":4935296},{"date":"2023-09-29","current":-0.546143,"twenty":-3.551056,"median":-2.338167,"eighty":-1.605284,"marketCap":5308884},{"date":"2023-10-06","current":-0.576484,"twenty":-3.535509,"median":-2.330801,"eighty":-1.598066,"marketCap":5603822},{"date":"2023-10-13","current":-0.56637,"twenty":-3.529416,"median":-2.317858,"eighty":-1.582702,"marketCap":5505509},{"date":"2023-10-20","current":-0.529961,"twenty":-3.529416,"median":-2.309344,"eighty":-1.582674,"marketCap":5151583},{"date":"2023-10-27","current":-0.515296,"twenty":-3.529416,"median":-2.303676,"eighty":-1.573299,"marketCap":5009030},{"date":"2023-11-03","current":-0.488595,"twenty":-3.529416,"median":-2.295319,"eighty":-1.555321,"marketCap":4749485},{"date":"2023-11-10","current":-0.420732,"twenty":-3.529416,"median":-2.279706,"eighty":-1.52544,"marketCap":4089807},{"date":"2023-11-17","current":-0.49227,"twenty":-3.529416,"median":-2.266533,"eighty":-1.497359,"marketCap":3974781},{"date":"2023-11-24","current":-0.519915,"twenty":-3.529416,"median":-2.255719,"eighty":-1.484111,"marketCap":4197997},{"date":"2023-12-01","current":-1.259878,"twenty":-3.529416,"median":-2.246954,"eighty":-1.471408,"marketCap":10172748},{"date":"2023-12-08","current":-0.944716,"twenty":-3.529416,"median":-2.243626,"eighty":-1.458806,"marketCap":7628004},{"date":"2023-12-15","current":-0.760271,"twenty":-3.529416,"median":-2.242091,"eighty":-1.44978,"marketCap":6138727},{"date":"2023-12-22","current":-0.781479,"twenty":-3.529416,"median":-2.242091,"eighty":-1.42203,"marketCap":6309968},{"date":"2023-12-29","current":-0.878907,"twenty":-3.529416,"median":-2.242858,"eighty":-1.409887,"marketCap":7096639},{"date":"2024-01-05","current":-1.166178,"twenty":-3.529416,"median":-2.243626,"eighty":-1.402478,"marketCap":9416175},{"date":"2024-01-12","current":-1.113479,"twenty":-3.529416,"median":-2.241771,"eighty":-1.377273,"marketCap":8990667},{"date":"2024-01-19","current":-0.798188,"twenty":-3.529416,"median":-2.240902,"eighty":-1.367144,"marketCap":6444885},{"date":"2024-01-26","current":-0.76477,"twenty":-3.529416,"median":-2.232464,"eighty":-1.350711,"marketCap":6175051},{"date":"2024-02-02","current":-0.861041,"twenty":-3.529416,"median":-2.232464,"eighty":-1.323591,"marketCap":6952381},{"date":"2024-02-09","current":-0.832892,"twenty":-3.529416,"median":-2.232464,"eighty":-1.284479,"marketCap":6725098},{"date":"2024-02-16","current":-0.935719,"twenty":-3.529416,"median":-2.232464,"eighty":-1.19338,"marketCap":7555357},{"date":"2024-02-23","current":-0.96014,"twenty":-3.529416,"median":-2.232464,"eighty":-1.170061,"marketCap":7752543},{"date":"2024-03-01","current":-0.937004,"twenty":-3.529416,"median":-2.232314,"eighty":-1.094071,"marketCap":7565735},{"date":"2024-03-08","current":-1.015409,"twenty":-3.529416,"median":-2.232314,"eighty":-1.04266,"marketCap":8198808},{"date":"2024-03-15","current":-0.818497,"twenty":-3.529416,"median":-2.232314,"eighty":-0.985743,"marketCap":6608861},{"date":"2024-03-22","current":-1.096879,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6735639},{"date":"2024-03-28","current":-1.040493,"twenty":-3.529416,"median":-2.231918,"eighty":-0.985743,"marketCap":6389385},{"date":"2024-04-05","current":-0.805692,"twenty":-3.529416,"median":-2.232163,"eighty":-0.951971,"marketCap":4947537},{"date":"2024-04-12","current":-0.666183,"twenty":-3.529416,"median":-2.232163,"eighty":-0.937467,"marketCap":4090848},{"date":"2024-04-19","current":-0.746049,"twenty":-3.529416,"median":-2.232163,"eighty":-0.925458,"marketCap":4581287},{"date":"2024-04-26","current":-0.990316,"twenty":-3.529416,"median":-2.231918,"eighty":-0.92158,"marketCap":6081264},{"date":"2024-05-03","current":-0.938133,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5760823},{"date":"2024-05-10","current":-0.941612,"twenty":-3.529416,"median":-2.231918,"eighty":-0.914511,"marketCap":5782185},{"date":"2024-05-17","current":-0.792348,"twenty":-3.529416,"median":-2.231918,"eighty":-0.90316,"marketCap":5554316},{"date":"2024-05-24","current":-0.729366,"twenty":-3.529416,"median":-2.231918,"eighty":-0.885025,"marketCap":5112819},{"date":"2024-05-31","current":-0.711081,"twenty":-3.529416,"median":-2.231918,"eighty":-0.868111,"marketCap":4984642},{"date":"2024-06-07","current":-0.584609,"twenty":-3.529416,"median":-2.231918,"eighty":-0.841478,"marketCap":4098079},{"date":"2024-06-14","current":-0.584609,"twenty":-3.529416,"median":-2.232163,"eighty":-0.825714,"marketCap":4098079},{"date":"2024-06-21","current":-0.5184,"twenty":-3.529416,"median":-2.232314,"eighty":-0.813414,"marketCap":3633959},{"date":"2024-06-28","current":-0.373304,"twenty":-3.529416,"median":-2.233626,"eighty":-0.808757,"marketCap":2616845},{"date":"2024-07-05","current":-0.318365,"twenty":-3.529416,"median":-2.233626,"eighty":-0.804561,"marketCap":2231725},{"date":"2024-07-12","current":-1.077653,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7554290},{"date":"2024-07-15","current":-1.046662,"twenty":-3.529416,"median":-2.233626,"eighty":-0.801249,"marketCap":7337043},{"date":"2024-08-02","current":-0.618418,"twenty":-3.535509,"median":-2.215749,"eighty":-0.797123,"marketCap":4335076},{"date":"2024-08-09","current":-0.442331,"twenty":-3.535509,"median":-2.205592,"eighty":-0.792348,"marketCap":3100715},{"date":"2024-08-16","current":-1.081532,"twenty":-3.535509,"median":-2.189844,"eighty":-0.792348,"marketCap":7616606},{"date":"2024-08-23","current":-1.372962,"twenty":-3.535509,"median":-2.17772,"eighty":-0.792348,"marketCap":9668985},{"date":"2024-08-30","current":-1.058865,"twenty":-3.535509,"median":-2.174327,"eighty":-0.792348,"marketCap":7456976},{"date":"2024-09-06","current":-1.343819,"twenty":-3.535509,"median":-2.166303,"eighty":-0.792348,"marketCap":9463747},{"date":"2024-09-13","current":-1.110675,"twenty":-3.535509,"median":-2.161246,"eighty":-0.792348,"marketCap":7821844},{"date":"2024-09-20","current":-1.240199,"twenty":-3.535509,"median":-2.156951,"eighty":-0.792348,"marketCap":8734012},{"date":"2024-09-27","current":-1.246676,"twenty":-3.535509,"median":-2.145374,"eighty":-0.792348,"marketCap":8779620},{"date":"2024-10-04","current":-1.279057,"twenty":-3.535509,"median":-2.13956,"eighty":-0.792348,"marketCap":9007662},{"date":"2024-10-11","current":-1.292009,"twenty":-3.535509,"median":-2.13101,"eighty":-0.792348,"marketCap":9098879},{"date":"2024-10-18","current":-1.175437,"twenty":-3.535509,"median":-2.12822,"eighty":-0.792348,"marketCap":8277928},{"date":"2024-10-25","current":-1.20458,"twenty":-3.535509,"median":-2.123577,"eighty":-0.792348,"marketCap":8483166},{"date":"2024-10-31","current":-1.207818,"twenty":-3.535509,"median":-2.107658,"eighty":-0.792348,"marketCap":8505970},{"date":"2024-11-08","current":-1.123627,"twenty":-3.535509,"median":-2.074279,"eighty":-0.792348,"marketCap":7913060},{"date":"2024-11-15","current":-1.300862,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":9234956},{"date":"2024-11-22","current":-1.187744,"twenty":-3.535509,"median":-2.067722,"eighty":-0.792348,"marketCap":8431916},{"date":"2024-11-29","current":-1.184209,"twenty":-3.535509,"median":-2.049939,"eighty":-0.792348,"marketCap":8406821},{"date":"2024-12-06","current":-1.131184,"twenty":-3.535509,"median":-2.033927,"eighty":-0.792348,"marketCap":8030396},{"date":"2024-12-13","current":-1.170069,"twenty":-3.535509,"median":-2.017112,"eighty":-0.792348,"marketCap":8306441},{"date":"2024-12-20","current":-1.088765,"twenty":-3.535509,"median":-2.001581,"eighty":-0.792348,"marketCap":7729256},{"date":"2024-12-27","current":-1.021601,"twenty":-3.535509,"median":-1.986209,"eighty":-0.792348,"marketCap":7252452},{"date":"2025-01-03","current":-1.039276,"twenty":-3.535509,"median":-1.976601,"eighty":-0.792348,"marketCap":7377927},{"date":"2025-01-10","current":-1.155929,"twenty":-3.529416,"median":-1.97197,"eighty":-0.792348,"marketCap":8206061},{"date":"2025-01-17","current":-0.802434,"twenty":-3.523734,"median":-1.964077,"eighty":-0.792348,"marketCap":5696562},{"date":"2025-01-24","current":-0.887273,"twenty":-3.508918,"median":-1.953718,"eighty":-0.792348,"marketCap":6298842},{"date":"2025-01-31","current":-0.816574,"twenty":-3.487384,"median":-1.94499,"eighty":-0.792348,"marketCap":5796942},{"date":"2025-02-07","current":-0.830713,"twenty":-3.464081,"median":-1.928314,"eighty":-0.792348,"marketCap":5897322},{"date":"2025-02-14","current":-0.869598,"twenty":-3.460004,"median":-1.914564,"eighty":-0.792348,"marketCap":6173367},{"date":"2025-02-21","current":-0.862528,"twenty":-3.449367,"median":-1.905104,"eighty":-0.792348,"marketCap":6123177},{"date":"2025-02-28","current":-0.795364,"twenty":-3.435067,"median":-1.886817,"eighty":-0.792348,"marketCap":5646372},{"date":"2025-03-07","current":-0.823644,"twenty":-3.423562,"median":-1.846485,"eighty":-0.790373,"marketCap":5847132},{"date":"2025-03-14","current":-0.813039,"twenty":-3.41639,"median":-1.80975,"eighty":-0.790373,"marketCap":5771847},{"date":"2025-03-21","current":-0.841318,"twenty":-3.407348,"median":-1.782714,"eighty":-0.790373,"marketCap":5972607},{"date":"2025-03-28","current":-0.866528,"twenty":-3.405471,"median":-1.77383,"eighty":-0.790373,"marketCap":7163218},{"date":"2025-04-04","current":-0.794114,"twenty":-3.378355,"median":-1.754307,"eighty":-0.790373,"marketCap":6564600},{"date":"2025-04-11","current":-0.72147,"twenty":-3.370724,"median":-1.718749,"eighty":-0.782944,"marketCap":5964089},{"date":"2025-04-17","current":-0.786365,"twenty":-3.368231,"median":-1.700232,"eighty":-0.779049,"marketCap":6500542},{"date":"2025-04-25","current":-0.822629,"twenty":-3.349519,"median":-1.687952,"eighty":-0.778595,"marketCap":6800324},{"date":"2025-05-02","current":-0.732922,"twenty":-3.335701,"median":-1.677345,"eighty":-0.767341,"marketCap":6058757},{"date":"2025-05-09","current":-0.752009,"twenty":-3.318337,"median":-1.658339,"eighty":-0.75921,"marketCap":6216537},{"date":"2025-05-16","current":-0.625327,"twenty":-3.306695,"median":-1.64132,"eighty":-0.752009,"marketCap":5995645},{"date":"2025-05-23","current":-0.623044,"twenty":-3.300954,"median":-1.631589,"eighty":-0.744363,"marketCap":5973753},{"date":"2025-05-30","current":-0.653685,"twenty":-3.291097,"median":-1.613804,"eighty":-0.737916,"marketCap":6267544},{"date":"2025-06-06","current":-0.626449,"twenty":-3.282404,"median":-1.587127,"eighty":-0.732937,"marketCap":6006396},{"date":"2025-06-13","current":-0.626449,"twenty":-3.276897,"median":-1.572151,"eighty":-0.718851,"marketCap":6006396},{"date":"2025-06-18","current":-0.61283,"twenty":-3.273592,"median":-1.563577,"eighty":-0.712183,"marketCap":5875822}],"updateTime":1750472360881}}}